Welcome to CrownBio’s Blog where we share our thoughts
on the latest trends and hot stories in Oncology and CVMD

August 24, 2017 Mouse Allograft Models: A GEMM-Derived Efficacy Testing Platform Genetically engineered mouse models (GEMM) were reviewed in a recent post, as immunocompetent, murine immunity models for immuno-oncology assays. While highly useful for monitoring cancer progression and mechanism of action studies, the spontaneous nature of GEMM tumors makes them complex and costly models for efficacy studies. LEARN MORE
August 22, 2017 The Beginners Guide to Neoantigens and Immuno-Oncology Studies \Neoantigens are mutation associated antigens that arise from nonsynonomous somatic variations acquired in tumors ... LEARN MORE
August 17, 2017 How to Optimize your Non GLP Toxicology Studies Most new drug candidates fail in the clinic because they are not efficacious or are not safe. Optimizing non-clinical ... LEARN MORE
August 15, 2017 Genetically Engineered Mouse Models (GEMM) for I/O Studies Led largely by the growth in immuno-oncology research, older immunocompetent model use continues to rise. These models ... LEARN MORE
August 10, 2017 Tumor Necrosis Factor Superfamily of Ligands and Receptors 101 Members of the large Tumor Necrosis Factor (TNF) superfamily (TNFSF) of proteins participate in the coordinated ... LEARN MORE
August 8, 2017 Syngeneic Tumor Mouse Models: The Pros and Cons Immunotherapeutics are bringing remarkable survival rates for certain cancer patients, but they are also bringing some ... LEARN MORE
August 3, 2017 How Patient Derived Tumor Grafts (PDX) Accelerate Early Drug Development × Over the year’s cancer research and drug development have moved from developing “simple” chemotherapies which stop tumors proliferating, onto the innovative field of precision medicine, based on the genetic changes and make up of individual patient tumors. LEARN MORE
August 1, 2017 NASH Drug Development Race Intensifies There is no FDA-approved treatment for NASH, which affects 3-5% of Americans. Competition to deliver the first ... LEARN MORE
July 27, 2017 Polycystic Kidney Disease (PKD): The Argument for Multiple Rodent Models Rodent models of PKD are critical to studying both its molecular basis and progression, but the complexity of ... LEARN MORE
July 25, 2017 Precision Medicine: First Multi-Agent Next-Generation Sequencing Companion Diagnostic Test Approved by the FDA Following our recent blog covering the first US FDA approval for a cancer treatment based on a biomarker regardless of ... LEARN MORE
July 20, 2017 Overcoming the Tumor Microenvironment and Heterogeneity to Improve Preclinical Response It is well known that the tumor microenvironment is quite complex to model preclinically. A major challenge we face is that there are numerous different cancer types along with many different mutations that make up the diversity of cancers. Therefore, the path each malignancy evolves proves to be very different. × LEARN MORE
July 18, 2017 Overcoming Acquired Resistance with PDX Targeted therapies have been very successful in cancer treatment. Approved for a range of targets across many cancer ... LEARN MORE
July 18, 2017 How to Use PDX in Immuno-Oncology Studies Patient-derived xenografts (PDX) are a commonly used preclinical drug development tool, engrafted into immunodeficient ... LEARN MORE
July 13, 2017 Progress Towards a Cure for Polycystic Kidney Disease Polycystic kidney disease (polycystic kidney syndrome, PKD, or PCKD) is a genetic disorder in which numerous abdominal ... LEARN MORE
July 11, 2017 Oncolytic Viruses: From History to Where We Go Next One of the more innovative weapons in our anticancer armamentarium has to be oncolytic viruses. Their rationale as an ... LEARN MORE